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Abstract: 
The most common types of chronic inflammatory arthritis are rheumatoid arthritis (RA), psoriatic 
arthritis (PsA) and ankylosing spondylitis (AS). In order to assess the activity of these diseases and 
tailor therapy, several outcome measures have been developed. They include composite scores 
based on clinical findings, biochemical markers and patient questionnaires. This article aims to 
discuss the most commonly used outcome measures and discuss their limitations in quantifying the 
complex clinical features of different types of inflammatory arthritis, focusing in particular on RA, 
PsA and AS. 
 
Introduction: 
Inflammatory arthritis broadly encompasses rheumatoid arthritis (RA), psoriatic arthritis (PsA) and 
ankylosing spondylitis (AS). They are chronic autoimmune inflammatory conditions, which if left 
untreated lead to severe morbidity and increased mortality. One third of patients newly diagnosed 
with RA stop work within two years (Nice.org.uk). Early detection and aggressive immunosuppression 
with disease-modifying anti-rheumatic drugs (DMARDs) is required in order to achieve remission and 
reduce joint damage. To attain this goal and prevent the overuse of immunosuppressive medications, 
which have their own risks, several outcome measures assessing disease activity have been 
developed. The outcome measures used in rheumatologic practice frequently include composite 
scores, based on clinical findings, biochemical markers and patient reported outcome measures 
(PROMS). There are numerous outcome measures for RA, PsA and AS (Table 1). The purpose of this 
article is to discuss the most commonly used ones, including when they should be used in routine 
practise, their benefits and limitations. 
RA 
RA is a chronic systemic inflammatory disease characterised by multiple joint involvement. Its 
presentation is highly variable within individuals and between patients. Patients often experience 
significant joint pain, stiffness, fatigue and functional impairment. Since the first composite disease 
activity measurement tool was developed in the 1950s, researchers designed and validated another 
63. Of these, the most commonly used and recommended by the American College of Rheumatology 
(ACR) and European League Against Rheumatism (EULAR), are:   
1. Disease Activity Score with 28-joint counts (DAS28),  
2. Clinical Disease Activity Index (CDAI),  
3. Patient Activity Scale (PAS),  
4. Routine Assessment of Patient Index Data 3 (RAPID3)  
5. Simple Disease Activity Index (SDAI) (Anderson et al, 2012).  
These measurement tools can guide clinician treatment decision and indicate when clinical remission 
is reached.  
The DAS28 score is the most recognised disease activity score and incorporates twenty eight joints 
that are assessed for tenderness and swelling (Figure 1). The patient is asked to score the severity of 
their disease (global health) on a scale of 0-100. Blood markers of inflammation (ESR or CRP) are 
incorporated and using these four variables, a complex mathematical formula is used to produce the 
overall disease activity score. A DAS28 score >5.1 implies active disease, a score between 3.2-5.1 
signifies moderate disease activity, less than 3.2 equates to low disease activity, and <2.6 implies 
remission. A DAS 28 score should be performed on all patients with newly diagnosed RA, and this 
should be repeated at monthly treatment intervals until a low disease activity target is reached 
(Nice.org.uk). The National Institute for Health and Care Excellence (NICE) recommend that patients 
with a DAS28 score greater than 5.1 on two conventional DMARDs are eligible for biologic therapy. 
The CDAI score incorporates the assessment of 28 joints for tenderness and swelling. The patient is 
asked to provide a global assessment of disease activity on a scale of 0-10, and the assessor grades 
the patient’s global disease activity out of 10. All of the above values are added up to give a total score. 
Scores 22.1-76 equal high disease activity, 10.1-22 define moderate activity, 2.9-10 represent low 
disease activity, and 0-2.8 suggest remission (Rheumatology.org). This assessment tool is quick to use 
as it does not include inflammatory markers, and hence its use is particularly useful when no recent 
blood test results are available. 
The SDAI score is similar to CDAI score except that it incorporates the patient’s CRP value, which is 
assumed to be within the interval 0-10mg/dl. Therefore the maximum score is 86. Once again, scores 
are grouped into remission, low, moderate and high disease activity (Rheumatology.org). 
RAPID3 score is a patient reported outcome comprising numerous questions about the patients’ 
function in the last week, their level of pain, and their global health. Scores are allocated depending 
on the patient’s answers and are weighted. The maximum total score is 10 indicating high severity of 
disease if above 4, moderate severity if more than 2.3 and less than 4, and near remission if lower 
than 1 (Rheumatology.org). This assessment is quick to perform and can be completed by patients 
whilst awaiting their rheumatology consultation.  
Another tool used for appreciation of disease severity in RA is PAS, which is a functional assessment 
of patient’s everyday activities, walking ability and use of equipment aides, need for assistance, and 
level of pain over the last week. 
The consensus is that the best outcome measure scores involve a combination of patient and physician 
assessments (Anderson et al, 2012). However, clinical assessment of disease performed by a trained 
health professional can be time consuming despite being more accurate and thus patient-reported 
outcome measures have been implemented in practice. It can be argued that by making patients 
responsible for their own assessment provides greater patient-centred care, and improves 
engagement and therapy compliance. A recent systematic review of PROMS used to assess disease 
activity in RA found that the patient derived disease activity score with 28 joint counts (Pt-DAS28), 
Rheumatoid Arthritis Disease activity index (RADAI) and RAPID 3 score had the strongest and most 
extensive validation (Hendrikx et al, 2016).  
The ACR criteria of response are the standard benchmarks used to measure the effectiveness of 
various DMARDs. There are three main criteria; designated as ACR 20, ACR 50 and ACR 70 response 
criteria. The numbers signify the percentage of improvement of disease activity between two discrete 
time points. The ACR criteria measure tender and swollen joints, patient and physician’s disease 
activity assessments on a scale 0-10, pain severity on scale 0-10, disability/functional scores and 
inflammatory markers (ESR or CRP). 
The EULAR response criteria classifies patients as either non-responders, moderate or good 
responders depending on two DAS28 scores taken between two discrete time points.  The DAS28 
score is a measure of disease activity at a certain time point rather than measurement of change such 
as the ACR response criteria (Fransen et al, 2005). Both assessments allow clinicians to determine 
whether certain treatments are effective or not. The ACR and EULAR criteria are therefore used in 
clinical trials and current practice, and when compared against each other, there was less than 3% 
discrepancy in their appreciation of patient response to treatment (van Gestel et al, 1999). 
AS 
AS is a chronic inflammatory disease of unknown aetiology characterised by inflammation of spinal 
joints and adjacent structures, which untreated leads to progressive bony fusion of the spine (Davis et 
al, 2005). AS has a genetic predisposition proven by its strong association with human leukocyte 
antigen B27 (HLA-B27). 
The assessment of AS activity comprises objective signs of inflammation and assessment of the 
severity of patients’ subjective symptoms. This includes the number of swollen and/or tender joints, 
the number of inflamed entheses, spinal pain, fatigue, and duration of morning stiffness. Laboratory 
markers of inflammation may be helpful, but are not incorporated in all outcome measure scoring 
systems used in AS, as they do not always correlate with the objective evidence of spinal inflammation. 
Outcome measures are important to guide for DMARD therapies selection in AS (van der Heijde et al 
1997). Disease activity in AS is measured by several scores; the most used ones are detailed below. 
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (Garett et al, 1994), (Figure 2) is a 
patient’s reported outcome questionnaire using a visual analogue scale of 0 to 10 to assess the 
following criteria: A. fatigue,  B. spinal pain, C. joint pain, D. enthesitis,  E. qualitative morning stiffness 
and F. quantitative morning stiffness.  The BASDAI score is calculated using the following formula: 
BASDAI = 0.2 (A +B + C +D + 0.5[E + F]). Patients who have a BASDAI score greater than 4 despite non-
steroidal anti-inflammatory drugs may be eligible for biological DMARD therapy. 
The Bath Ankylosing Spondylitis Functional Index (BASFI) appreciates the physical function of patients 
with AS through a self-assessment questionnaire, and it is reported as mean score of 10 questions 
answered using a visual analogue scale 0 to 10. Eight questions relate to patient’s functional ability, 
and two questions relate to the patient’s capacity to cope with everyday life.  Any increase in the 
reposted score between two different time points indicates a worsening disease condition (Calin et al 
1994). 
The Bath Ankylosing Spondylitis Metrology Index (BASMI) is an aggregate score of five different 
objective measures of spinal mobility, which includes:  lateral lumbar flexion, tragus-to-wall distance, 
lumbar flexion (modified Schober’s test), intermalleolar distance and cervical rotation angle. Each 
parameter is calculated as a mean of right and left measurement.  BASMI was used to determine the 
minimum number of clinically appropriate measurements that assess accurately axial mobility status 
to define clinically significant changes in spinal movement (van der Heijde et al, 2008).  
The Maastrich Ankylosing Spondylitis Enthesitis Score (MASES index) (Heuft-Dorenbosch et al, 2003) 
was developed to assess enthesitis (inflammation of entheses) in patients with AS. The MASES index 
helps evaluate for the presence and absence of pain at the site of entheses, by applying local pressure 
to the following areas: 1st costochondral joint (left and right), 7th costochondral joint (left and right), 
posterior superior iliac spine (left and right), anterior superior iliac spine (left and right), iliac crest (left 
and right), 5th lumbar spinous process, and proximal insertion of Achilles tendon (left and right).  The 
range of MASES index is 0 to 13. 
PsA 
PsA is a seronegative chronic inflammatory arthritis, which can manifest as peripheral joint 
inflammation, enthesitis, dactylitis and axial inflammation. Up to 40% of patients also have skin and 
nail involvement (Coates et al, 2012). Core outcome measures and domain sets have been set out by 
the collaborative research Group of Research and Assessment of Psoriasis and Psoriatic Arthritis 
(GRAPPA) and the Outcome Measures in Rheumatology group (OMERACT) (Mease, 2011). They have 
attempted to standardise measurements of disease used in randomised clinical trials to reflect both 
patients’ and physicians’ priorities. However, specific guidance for their use in the routine clinical 
rheumatology practice is lacking. There are few instruments specifically designed for measuring 
disease severity. Many outcome measures (such as peripheral joint disease, patient and physician 
global assessments, and axial disease) are adapted from the scores used in other similar conditions 
like RA and AS (Mease, 2011). 
Evaluation of disease activity should include assessment of joints (peripheral arthritis, enthesitis, 
dactylitis, and spinal symptoms) and skin (severity of psoriasis, including psoriatic nail disease) 
(Gladman et al, 2004). Other domains include pain, patient and physician global assessment, physical 
function, HRQoL, fatigue and systemic inflammation (Orbai et al., 2016). 
Peripheral joint disease 
There are no widely validated and specific measures of peripheral joint disease for PsA (Gladman et 
al., 2007). In clinical practice, a 28 joint count as in RA is often performed. However, an extended joint 
count score assessing 66 joints for swelling, and 68 joints tenderness is frequently used in research 
settings (Gladman et al, 2007). The Psoriatic Response Criteria (PsARC), which was designed initially 
for a clinical trial of sulfasalazine, is another tool used for assessment of response to treatment in PsA; 
although not validated (Gladman et al, 2007). PsARC measures tender and swollen joint scores, 
physician global and patient global assessments of disease activity (0-5 point Likert scales). Overall 
improvement is defined as an improvement in minimum two of the four items, one of which must be 
joint count, without worsening of any items.  
Dactylitis 
Dactylitis, or sausage digit, is a hallmark clinical feature reported in 16-48% of PsA patients (Gladman 
et al, 2007). It is described as a uniform diffuse swelling of the soft tissues between 
metacarpophalangeal, proximal and distal interphalangeal joints - The Leeds Dactylitis Instrument 
(LDI) provides an objective assessment by measuring the diameter (cm) for each digit affected and its 
tenderness score. A 10% difference in diameter between bilateral finger measurements indicates 
dactylitis. The LDI has demonstrated good inter- and intra-observer reliability and provides an 
objective measure of this feature (Gladman et al, 2007). 
Enthesitis 
Enthesitis is characterised as inflammation at the sites of tendon, ligament and joint capsule fibre 
insertion into the bone (Mease, 2011). Although enthesitis is a common feature of PsA, the enthesitis 
scores used in PsA have been adapted from AS. The Leeds Enthesitis Index (LEI) assesses the presence 
or absence of tenderness on palpation at six keys sites: both lateral epicondyles; medial epicondyles; 
and Achilles tendons. The LEI score showed good sensitivity to change following effective treatment 
(Gladman et al, 2007). 
Axial disease 
Incidence of spinal involvement in PsA is reported between 20-70% patients (Gladman et al, 2007). 
Although axial disease is considered to be less severe in PsA patients compared to AS patients, many 
of the outcome measures used in AS are applicable to PsA. 
Nail disease 
Psoriatic nail changes are associated with higher joint counts and disease activity (Sandre, Rohekar 
and Guenther, 2015). The Nail Psoriasis Severity Index (NAPSI) is a simple objective tool to evaluate 
changes in colour, the thickness and features of the nail plate and matrix (Gladman et al, 2007). 
Features of nail psoriasis include nail pitting, crumbling, onycholysis, oil drop dyschromia, splinter 
haemorrhages, leukonychia, and red spots (Figure 3). The modified NASPI score (m-NAPSI), improved 
following GRAPPA focus group discussions have enhanced its feasibility and face validity. 
Skin Assessment 
Skin assessment is not a direct measure of PsA activity in rheumatology settings, as psoriasis is only 
present in 40% of PsA patients. The Psoriasis area and severity index (PASI) is the most widely used 
assessment tool for skin psoriasis (Mease, 2011). It measures the erythema, induration, scale and area 
affected by psoriasis, and can be re-measured at regular intervals to evaluate the effectiveness of 
treatment (Hughes and van Onselen, 2001). Rheumatologists often use subjective measures including 
patient and physician global assessment of psoriasis disease activity, comprising of visual analogue 
scales (VAS). 
Conclusions: 
Disease activity measuring tools allow clinicians to assess the severity of rheumatic conditions, which 
can act as guidance on when to escalate/reduce medical therapy. Low disease activity scores indicate 
disease remission, providing reassurance to the clinician that the risk of long-term irreversible joint 
damage is significantly reduced. They play an important role in research studies as a standardised 
assessment tools, allowing potential new therapies to be compared to current treatment. Composite 
outcome measures can also offer information about disease impact on patient’s quality of life. These 
assessments can support clinicians in involving members of the multi-disciplinary team in the provision 
of patient’s care, ultimately improving patient outcomes. Patients can also complete some assessment 
tools before seeing a rheumatologist, therefore maximising the time and quality of the consultation. 
However, these tools have their limitations. Firstly, patient’s scores often include pain as a reported 
outcome, which is subjected to wide variations in patient’s perceptions of pain. A stoical patient’s pain 
score will significantly underestimate underlying disease activity, as opposed to a patient with a low 
pain threshold. Those patients with multiple co-morbidities are also difficult to assess clinically, as how 
they feel may be related to several conditions as opposed to just their underlying rheumatic disease. 
The same applies to those with chronic pain/fibromyalgia. Secondly, there can be variations between 
assessors in their perception of swollen and pressure applied to elicit joint tenderness, depending on 
the level of skills and experience of the assessor. 
Inflammatory arthropathies encompass a wide variety of presentations that pose challenges in 
assessing overall disease activity. An objective measure may assess a single aspect of the disease but 
does not include the psychological impact of the disease on patient’s quality of life. The Health 
assessment questionnaire (HAQ) is recommended by NICE for use in practice, as it identifies physical 
limitations of everyday tasks. It should be performed every 6 or 12 months. Another patient 
questionnaire, the Quality of Life Index is a very useful tool to assess psychological well-being, as 
depression is common in patients with arthritis. Radiographic damage scores also have a role as 
outcome measures in arthritis, and it is useful to request x-rays at the time of diagnosis, with further 
imaging performed when new symptoms arise or at set time points, to identify irreversible joint 
changes that would suggest ongoing chronic inflammation. There is also an emerging role in the use 
of joint ultrasound examination in patients with RA and PsA, which can detect sub-clinical synovitis. 
Composite scores, combining clinical and imaging outcomes are likely to become more common. 
Overall, there is no doubt that disease activity measuring tools are of significant benefit, and allow 
quantification and comparisons between patient’s disease activity levels over time and between larger 
populations. We recommend regular use of DAS28, PsARC and BASDAI in follow-up appointments for 
inflammatory arthritis patients, as validated scores that were shown to improve therapeutic decisions 
and disease control over time, were associated with a significant patient benefit.  
Table 1: Outcome measures for inflammatory arthritis 
Type of 
inflammatory 
arthritis 
Rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis 
Peripheral 
joint 
involvement 
Tender joint count (TJC/28 
or 44 or 68) 
Swollen joint count (SJC/28 
or 44 or 66) 
Physician global rating (VAS) 
Patient global rating (VAS) 
Tender joint count 
(TJC/68) 
Swollen joint count 
(SJC/66) 
Physician global rating 
(Likert’s scale) 
Tender joint count 
(TJC/68) 
Swollen joint count 
(SJC/66) 
Enthesitis (LEI, MASES, 
MEI, enthesitis question 
on BASDAI) 
Patient pain rating (VAS) 
DAS 28 
CDAI 
SDAI 
RAPID 3 
ACR20 
ACR 50 
ACR 70 
EULAR and ACR response 
criteria 
Boolean remission criteria 
Inflammatory markers 
Radiographic progression 
(Steinbrocker, Sharp/Larsen 
scores) 
MRI progression (RAMRIS 
score) 
Patient global rating 
(Likert’s scale) 
DAS 28 
ACR20 
ACR 50 
ACR 70 
EULAR and ACR 
response criteria 
Dactylitis (LDI) 
Enthesitis (LEI, MASES) 
Nail disease (NAPSI) 
Inflammatory markers 
Radiographic 
progression (modified 
Steinbrocker, 
Sharp/Larsen, PARS 
scores) 
MRI progression 
(PsAMRIS score) 
 
Inflammatory markers 
 
Radiographic 
progression 
(Steinbrocker, 
Sharp/Larsen scores) 
Axial Joint 
involvement 
N/A BASDAI 
BASFI 
BASMI 
Spinal pain (VAS) 
ASDAS 
ASAS 20,50,70 
Spinal stiffness 
(stiffness question on 
BASDAI) 
Spinal enthesitis (MEI) 
Inflammatory markers 
BASDAI 
BASFI 
BASMI 
Spinal pain (VAS) 
ASDAS 
ASAS 20,50,70 
Spinal stiffness (stiffness 
question on BASDAI) 
Spinal enthesitis (MEI) 
Inflammatory markers 
Radiographic 
progression (mSASSS) 
MRI progression 
(ASspiMRI-a, Berlin and 
SPARCC scores) 
Radiographic 
progression (mSASSS) 
MRI progression 
(ASspiMRI-a, Berlin and 
SPARCC scores) 
 
Quality of life  
outcome 
measures 
HAQ  
SF-36  
EuroQol-5D 
 
HAQ 
PsAQoL  
SF-36  
EuroQol-5D 
HAQ  
SF-36  
EuroQol-5D 
ASQOL 
ASDAS = Ankylosing Spondylitis Disease Activity Score 
ASQOL = Ankylosing Spondylitis Quality of Life 
ASAS = Assessment of Spondyloarthritis 
ASspiMRI-a = Ankylosing Spondylitis spine Magnetic Resonance Imaging-activity 
EuroQol-5D = European Quality of Life 5 Domain score 
HAQ = Health Assessment Questionnaire 
LDI = Leeds Dactyitis Score 
LEI = Leeds Enthesitis Index (6 points) 
MASES = Maastricht Ankylosing Spondylitis Enthesitis Score (13 points) 
MEI = Maastricht Ankylosing Spondylitis Enthesitis Score (66 points) 
mSASSS = modified Stoke Ankylosing Spondylitis Spine Score 
PARS = Psoriatic Arthritis Ratingen Score 
PsAMRIS = Psoriatic arthritis- MRI scoring system 
PsAQoL = Psoriatic Arthritis Assessment of Quality of Life 
RAMRIS = Rheumatoid Arthritis-MRI scoring system 
SF-36 = Medical Outcomes Study Short Form 36 
SPARCC = Spondyloarthritis Research Consortium of Canada 
 
 
Figure 1: Disease Activity Score with 28-joint counts 
 
 
Figure 2: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)  
Garrett et al. J Rheumatol 1994 21; 2286-91 
 
Please tick the box which represents your answer. All questions refer to past week.  
 
1. How would you describe the overall level of fatigue/tiredness you have experienced? 
 
0  1  2  3  4  5  6  7  8  9  10 
          
None                                                                                                                                                very severe 
 
2. How would you describe the overall level of AS neck, back or hip pain you have had? 
0  1  2  3  4  5  6  7  8  9  10 
          
None                                                                                                                                               very severe 
 
3. How would you describe the overall level of pain/swelling in joints other than neck, back, hips you have had? 
 
0  1  2  3  4  5  6  7  8  9  10 
          
None                                                                                                                                                      very severe 
 
4. How would you describe the overall level of discomfort you have had from any  
areas tender to touch or pressure? 
 
0  1  2  3  4  5  6  7  8  9  10 
          
None                                                                                                                                                     very severe 
 
5. How would you describe the overall level of morning stiffness you have had from the time you wake up? 
 
0  1  2  3  4  5  6  7  8  9  10 
          
None                                                                                                                                                      very severe 
 
6. How long does your morning stiffness last from the time you wake up? 
                 _____________________________________________ 
                0 hrs                   ½                   1                   1½                2 or more hours 
 
Please add the scores (take the mean of stiffness questions 5 & 6) to give a score out of 50. Then multiply by 2 and 
divide by 10 to give a total BASDAI out of 10. 
 
Figure 3: Two psoriatic nails with pitting, crumbling, and onycholysis. 
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